BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 94 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q4 2021. The put-call ratio across all filers is 2.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $706 | -98.4% | 246 | -97.1% | 0.00% | – |
| Q2 2023 | $43,021 | +596.2% | 8,519 | +148.2% | 0.00% | – |
| Q4 2022 | $6,179 | -31.3% | 3,433 | -36.1% | 0.00% | – |
| Q3 2022 | $9,000 | -79.5% | 5,375 | -69.5% | 0.00% | – |
| Q2 2022 | $44,000 | -24.1% | 17,599 | -15.5% | 0.00% | – |
| Q1 2022 | $58,000 | -63.1% | 20,820 | -29.6% | 0.00% | – |
| Q4 2021 | $157,000 | +9.8% | 29,554 | +75.7% | 0.00% | – |
| Q3 2021 | $143,000 | +2.9% | 16,821 | +48.0% | 0.00% | – |
| Q2 2021 | $139,000 | -86.7% | 11,367 | -73.7% | 0.00% | – |
| Q1 2021 | $1,048,000 | +17366.7% | 43,189 | +21823.4% | 0.00% | – |
| Q3 2020 | $6,000 | -96.9% | 197 | -95.8% | 0.00% | – |
| Q2 2020 | $196,000 | +8.9% | 4,654 | -35.6% | 0.00% | – |
| Q1 2020 | $180,000 | – | 7,231 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
| NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
| MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
| Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
| RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
| Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
| Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
| Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |